[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335934-105":59,"doc-detail-335934-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognosis-prediction-and-risk-stratification-of-breast-cancer-patients-based-on-a-mitochondria-related-gene-signature","Prognosis prediction and risk stratification of breast cancer patients based on a mitochondria-related gene signature","","Breast cancer, the leading global malignancy in women, demands improved tools for prognosis and risk stratification. A mitochondria-related gene signature was developed to refine outcome prediction using transcriptome and clinical data from TCGA as training and METABRIC as independent validation. LASSO-Cox regression produced an 8-gene model, evaluated with ROC performance and combined with clinical variables in a Nomogram. Functional enrichment and immune infiltration, mutation landscape comparisons, and drug-sensitivity analyses distinguished high- versus low-risk groups, where the high-risk group showed worse survival and higher hazard.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognosis-prediction-and-risk-stratification-of-breast-cancer-patients-based-on-a-mitochondria-related-gene-signature/335934/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognosis-prediction-and-risk-stratification-of-breast-cancer-patients-based-on-a-mitochondria-related-gene-signature/335934.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which data sources were used to build and validate the mitochondrial-related gene signature?","Question",{"text":112,"@type":113},"Transcriptome data and clinical features were extracted from TCGA for training and METABRIC for independent validation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the prognostic signature constructed and evaluated?",{"text":117,"@type":113},"The signature was developed using LASSO-Cox regression and assessed for prognostic performance using ROC curves.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the key differences between high-risk and low-risk groups?",{"text":121,"@type":113},"Low-risk patients showed more favorable prognosis, enhanced immune infiltration, distinct mutation landscapes, and greater sensitivity to anti-tumor drugs, while high-risk patients showed worse trends across these aspects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335934,1790163873,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPrognosis prediction and risk stratification of breast cancer patients based  \non a mitochondria‑related gene signature  \nYang Wang1, Ding‑yuan Wang1, Ke‑na Bu2, Ji‑dong Gao 1,3* & Bai‑lin Zhang1*  \nAs the malignancy with the highest global incidence, breast cancer represents a significant threat to women’s health. Recent advances have shed light on the importance of mitochondrial function in cancer, particularly in metabolic reprogramming within tumors. Recognizing this, we developed a novel risk signature based on mitochondrial‑related genes to improve prognosis prediction and risk stratification in breast cancer patients. In this study, transcriptome data and clinical features of breast cancer samples were extracted from two sources: theTCGA, serving as the training set, and the METABRIC, used as the independent validation set. We developed the signature using LASSO‑ Cox regression and assessed its prognostic efficacy via ROC curves. Furthermore, the signature was integrated with clinical features to create a Nomogram model, whose accuracy was validated through clinical calibration curves and decision curve analysis. To further elucidate prognostic variations between high and low‑risk groups, we conducted functional enrichment and immune infiltration analyses. Additionally, the study encompassed a comparison of mutation landscapes and drug sensitivity, providing a comprehensive understanding of the differing characteristics in these groups. Conclusively, we established a risk signature comprising 8 mitochondrial‑related genes—ACSL1, ALDH2, MTHFD2, MRPL13, TP53AIP1, SLC1A1, ME3, and BCL2A1. This signature was identified as an independent risk predictor for breast cancer patient survival, exhibiting a significant high hazard ratio (HR = 3.028, 95%CI 2.038–4.499, P \u003C 0.001). Patients in the low‑risk group showed a more favorable prognosis, with enhanced immune infiltration, distinct mutation landscapes, and greater sensitivity to anti‑tumor drugs. In contrast, the high‑risk group exhibited an adverse trend in these aspects. This risk signature represents a novel and effective prognostic indicator, suggesting valuable insights for patient stratification in breast cancer.  \nAccording to GLOBOCAN 2020, female breast cancer has now overtaken lung cancer as the most prevalent malignant tumor globally, with an estimated 2.26 million new cases annually1. This alarming statistic highlights the urgent need for effective treatment strategies. Recent advancements in imaging screening2, surgical techniques3, radiotherapy4, and therapeutic drugs have markedly improved the prognosis for breast cancer patients. Nonetheless, the complexity and heterogeneity of breast cancer necessitate personalized treatment approaches5. The development of microarray and next-generation sequencing technologies has enabled polygenic testing, providing clinicians with additional clinical insights6. The significance of polygenic testing in breast cancer management has grown considerably, ranging from PAM50 for molecular typing7, to the 21-gene (Oncotype DX Breast Recurrence Score®)8 and MammaPrint™ 70-gene signature9, both of which are crucial in assessing clinical risk and informing treatment decisions in breast cancer cases.  \n1Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. 2Xingyuan Hospital of Yulin City, Yulin City 719051, Shanxi Province, China. 3Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union College, Shenzhen 518116, China. *email: ab168@ [cicams.ac.cn](cicams.ac.cn); [bailin_zhang@cicams.ac.cn](bailin_zhang@cicams.ac.cn)  \n[www. nature.com/scientificreports/](www. nature.com/scie","cbCaibxcsGOWN3oR","https://ap.wps.com/l/cbCaibxcsGOWN3oR","pdf",13281566,17,"English","# Background and rationale\n## Mitochondrial function in cancer\n# Methods and model development\n## Data sources: TCGA and METABRIC\n## LASSO-Cox regression and ROC evaluation\n## Nomogram integration and validation\n# Biological interpretation of risk groups\n## Functional enrichment\n## Immune infiltration\n## Mutation landscape and drug sensitivity\n# Results and clinical implication\n## 8-gene prognostic signature and survival association\n## High- vs low-risk group differences","[{\"question\":\"Which data sources were used to build and validate the mitochondrial-related gene signature?\",\"answer\":\"Transcriptome data and clinical features were extracted from TCGA for training and METABRIC for independent validation.\"},{\"question\":\"How was the prognostic signature constructed and evaluated?\",\"answer\":\"The signature was developed using LASSO-Cox regression and assessed for prognostic performance using ROC curves.\"},{\"question\":\"What are the key differences between high-risk and low-risk groups?\",\"answer\":\"Low-risk patients showed more favorable prognosis, enhanced immune infiltration, distinct mutation landscapes, and greater sensitivity to anti-tumor drugs, while high-risk patients showed worse trends across these aspects.\"}]","Prognosis prediction and risk stratification of breast cancer patients based on a mitochondria-related gene signature | PDF",1790012869,43]